CryoPort (NASDAQ:CYRX) Sets New 12-Month High – Here’s What Happened

Posted by Geri Gentry on Sep 21st, 2026

CryoPort, Inc. (NASDAQ:CYRX – Get Free Report)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $17.50 and last traded at $17.12, with a volume of 22232 shares trading hands. The stock had previously closed at $17.02.

Analysts Set New Price Targets

CYRX has been the topic of a number of analyst reports. Weiss Ratings lowered shares of CryoPort from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 17th. Roth Capital reissued a “buy” rating and issued a $21.00 price target on shares of CryoPort in a report on Friday, August 7th. Guggenheim boosted their price target on shares of CryoPort from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, August 7th. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price target on shares of CryoPort in a report on Friday. Finally, Craig Hallum increased their price objective on CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, June 3rd. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.00.

Check Out Our Latest Research Report on CryoPort

CryoPort Stock Performance

The firm has a market cap of $868.90 million, a PE ratio of -19.09 and a beta of 1.89. The stock’s 50 day simple moving average is $15.78 and its 200 day simple moving average is $13.36.

CryoPort (NASDAQ:CYRX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The company had revenue of $48.97 million for the quarter, compared to analysts’ expectations of $48.18 million. As a group, analysts anticipate that CryoPort, Inc. will post -0.83 earnings per share for the current year.

Insider Activity

In other news, CEO Jerrell Shelton sold 28,800 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the transaction, the chief executive officer directly owned 1,201,814 shares in the company, valued at approximately $17,919,046.74. This represents a 2.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

Institutional Trading of CryoPort

Several hedge funds and other institutional investors have recently bought and sold shares of CYRX. Basepoint Wealth LLC purchased a new position in shares of CryoPort during the fourth quarter worth approximately $34,000. AXQ Capital LP bought a new stake in shares of CryoPort in the 4th quarter worth approximately $125,000. Highland Investment Advisors LLC purchased a new stake in shares of CryoPort in the 2nd quarter valued at $306,000. Kerrisdale Advisers LLC purchased a new stake in shares of CryoPort in the 2nd quarter valued at $355,000. Finally, Engineers Gate Manager LP bought a new position in shares of CryoPort during the 2nd quarter valued at $518,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

(Get Free Report)

Cryoport, Inc (NASDAQ: CYRX) provides temperature-controlled logistics and supply-chain solutions for the life sciences industry. The company supports the transportation, storage and management of sensitive biological materials, including cell and gene therapies, biologics, vaccines, clinical-trial materials and reproductive tissues.

Its offerings include specialized cryogenic and refrigerated shipping systems, monitoring and tracking technologies, logistics coordination, packaging and storage services, and related bioservices.